ascorbic-acid and Iron-Metabolism-Disorders

ascorbic-acid has been researched along with Iron-Metabolism-Disorders* in 5 studies

Trials

2 trial(s) available for ascorbic-acid and Iron-Metabolism-Disorders

ArticleYear
Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 47, Issue:4

    Although erythropoietin (EPO)-hyporesponsive anemia in hemodialysis patients most commonly results from iron deficiency, the contributory role of chronic inflammation and oxidative stress in its pathogenesis is poorly understood. We conducted an open-label prospective study to assess the effect of vitamin C, an antioxidant, on EPO-hyporesponsive anemia in hemodialysis patients with unexplained hyperferritinemia.. Forty-six of 262 patients in an inner-city hemodialysis center met the inclusion criteria (administration of intravenous iron and EPO for > or = 6 months at a dose > or = 450 U/kg/wk, average 3-month hemoglobin [Hb] level < or = 11.0 g/dL [< or = 110 g/L], ferritin level > or = 500 ng/mL (microg/L), and transferrin saturation [TSAT] < or = 50%). Patients were excluded if they had a clear explanation for the EPO hyporesponsiveness. Four patients refused to participate. The remaining patients were randomly assigned; 20 patients to receive standard care and 300 mg of intravenous vitamin C with each dialysis session (group 1) and 22 patients to receive standard care only (group 2). Study duration was 6 months. During the study, 1 patient from group 1 was removed (upper gastrointestinal bleeding) from final analysis. Monthly assessment included Hb level, mean corpuscular volume, iron level, iron-binding capacity, ferritin level, TSAT, and Hb content in reticulocytes. In addition, biointact parathyroid hormone, aluminum, C-reactive protein (CRP), and liver enzymes were measured every 3 months.. Age, sex, race, and time on dialysis therapy were similar in both groups. At 6 months, Hb levels significantly increased from 9.3 to 10.5 g/dL (93.0 to 105.0 g/L) in group 1, but not group 2 (9.3 to 9.6 g/dL [93.0 to 96.0 g/L]; P = 0.0001). Similarly, TSAT increased from 28.9% to 37.3% in group 1, but not group 2 (28.7% to 29.3%; P = 0.0001). EPO dose (477 to 429 versus 474 to 447 U/kg/wk), iron-binding capacity (216 to 194 versus 218 to 257 microg/dL [38.7 to 34.7 versus 39 to 46 micromol/L]), and CRP level (2.8 to 0.9 versus 2.8 to 2.2 mg/dL) decreased significantly in group 1, but not in controls. Changes in Hb content in reticulocytes and ferritin level also were statistically significant in group 1. There was no change in biointact parathyroid hormone levels. Although serum iron levels and intravenous iron doses changed within each group, changes were equal between the 2 groups.. In hemodialysis patients with refractory anemia and hyperferritinemia, vitamin C improved responsiveness to EPO, either by augmenting iron mobilization from its tissue stores or through antioxidant effects.

    Topics: Adult; Anemia; Antioxidants; Ascorbic Acid; Erythropoietin; Female; Ferritins; Humans; Injections, Intravenous; Iron Metabolism Disorders; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Renal Dialysis

2006
[Ferro-folgamma--a good alternative in the treatment of iron deficiency anemia and depleted iron stores in pregnant women].
    Akusherstvo i ginekologiia, 2005, Volume: 44, Issue:7

    To study the effect of different therapeutical regimens of Ferro-Folgamma, in pregnant patients with iron deficiency anemia.. 22 pregnant patients between 20 and 35 week of gestation (mean 29 gestational week) with hemoglobin levels between 83.1-106 g/l were included. They were divided in two groups: group 1 included patients with hemoglobin levels up to 100g/l and group 2--with hemoglobin levels between 100 and 110. The dosage of the preparation in group 1 was 1 tablet Ferro-Folgamma tid for 40 days, and 1 tablet Ferro-Folgamma bid for the same period. Blood samples were taken four times during the study on day 0, 10th day, 20th day and in the week after the 40th completed day of therapy. The samples were tested for CBC, iron, transferine, feritine, folic acid. All patients were given complete information about the possible risks of iron deficiency anemia during pregnancy and parturition.. The mean hemoglobin level at initiation of treatment was 91.22 g/l (day 0). After initiation of treatment the the following rise in hemoglobin levels was detected 10th day - 103.8 g/l, 20th day - 112.6 g/l, after the 40th completed day - 136.0 g/l. The mean levels of the rest of hematological parameters were, day 0 - Er - 3.25 mln/microl, Fe - 7.53 micromol/l, transferine - 3.65 gr/l, feritine - 15.02 ngr/ml, folic acid - 14.08 ng/ml, vit. B12 - 219.68 pg/ml; 10th day - Er- 3.5 mln/microl, Fe - 14. 12 micromol/l; 20th day - Er - 4.10 mln/microl, Fe - 20.46 micromol/l; 40th completed day - Er- 4.69 mln/microl, Fe - 13.12 micromol/l, transferine - 3.82 gr/l, feritine - 27.42 ngr/ml, folic acid - 15.67 ng/ml, vit. B12 - 484.52 pg/ml respectively.. Oral treatment with Ferro-Folgamma, according the described dosage regimen, demonstrates its fast and stable effect in treatment of moderate iron deficiency and recovery of depleted iron pool in pregnant patients as well. It could be administered as a prophylactic preparation for borderline anemic states.

    Topics: Anemia, Iron-Deficiency; Ascorbic Acid; Drug Combinations; Female; Ferrous Compounds; Folic Acid; Gestational Age; Hemoglobins; Humans; Iron Metabolism Disorders; Pregnancy; Pregnancy Complications, Hematologic; Treatment Outcome

2005

Other Studies

3 other study(ies) available for ascorbic-acid and Iron-Metabolism-Disorders

ArticleYear
[The specific features of copper and manganese metabolism in the use of iron-containing preparations].
    Terapevticheskii arkhiv, 2012, Volume: 84, Issue:12

    To comparatively evaluate the efficiency of preventive treatment with various iron preparations on copper, manganese, and iron metabolic features in adult athletes.. Forty adult highly qualified sambo wrestlers were examined and divided into 4 groups of 10 persons in each. Group 1 athletes took iron-containing Sorbifer Durules in combination with ascorbic acid; Group 2 received Ferro Gradumet Vitamin C; Group 3 had Hemofer and ascorbic acid; Group 4 took ascorbic acid tablets. The latter group served as a control. Blood samples (15-20 ml) to be tested were taken at the beginning and end of 2-week use of iron preparations. The daily balance of iron, copper, and manganese was estimated following 7-day intake of these preparations.. The use of iron-containing preparations in combination with ascorbic acid was ascertained to be accompanied by an increment in the plasma concentration of iron and blood corpuscles, indicating an increased need for this biotic and its deficiency in athletes. When the dose of iron was increased in the iron preparations, there was a substantial rise in the excretion of copper, manganese in particular, through the gastrointestinal tract and kidney and a negative balance of these trace elements in the body.. Dietary addition of foods containing large amounts of ferrous iron, copper, and manganese is indicated for athletes exposed to higher intensity exercises.

    Topics: Adult; Ascorbic Acid; Athletes; Copper; Diet Therapy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Iron; Iron Compounds; Iron Deficiencies; Iron Metabolism Disorders; Male; Manganese; Metabolic Clearance Rate; Primary Prevention; Spectrum Analysis; Sports; Trace Elements; Vitamins

2012
Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
    Renal failure, 2008, Volume: 30, Issue:9

    To determine the efficacy and effects of the oral administration of ascorbic acid on anemia management in ESRD patients with hyperferritinemia.. Twenty-one anemic hemodialysis patients with ferritin levels greater than 350 ng/mL had received oral daily ascorbic acid at a dose of 500 mg/day and were retrospectively studied. Hemoglobin, hematocrit, EPO dose, ferritin, and transferrin saturation were recorded at baseline and after three months of treatment. EPO dose/hematocrit was calculated. Serum oxalate levels were also measured.. Hb increased 9% from 11.4 to 12.2 gm/dL (p = 0.05), HCT increased 10% from 33.3 to 36.7% (p = 0.05), but EPO dose requirement decreased 33% from 26,229 to 17,559 U/week (p = 0.03). Ferritin levels decreased 21% from 873 to 691 ng/mL (p = 0.004). Mean oxalate level during therapy was 87 micromol/L (normal <27). Patients with oxalate levels >27 micromol/L were instructed to stop ascorbic acid treatment, and mean levels decreased from 107 to 19 micromol/L (p = 0.01) over a mean time of 71 days.. In this study, daily oral ascorbic therapy decreased ferritin levels and EPO dose requirements while raising hemoglobin and hematocrit level. This beneficial profile of effects of ascorbic acid therapy is consistent with improvement of EPO resistance and cost savings in this population.

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Ascorbic Acid; Cohort Studies; Drug Administration Schedule; Female; Ferritins; Humans; Iron Metabolism Disorders; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vitamins

2008
STUDIES OF THE MECHANISM OF IRON ABSORPTION. II. INFLUENCE OF IRON DEFICIENCY AND OTHER CONDITIONS ON IRON UPTAKE BY RATS.
    The Journal of laboratory and clinical medicine, 1963, Volume: 62

    Topics: Ascorbic Acid; Deficiency Diseases; Iron; Iron Isotopes; Iron Metabolism Disorders; Pharmacology; Rats; Research; Sorbitol; Succinates

1963
chemdatabank.com